Compound Library

348+ Compounds. Zero Bro-Science.

Evidence-based profiles across healing peptides, GH secretagogues, GLP-1s, SARMs, steroids, nootropics, supplements, PCT ancillaries, and longevity compounds — with pharmacokinetics, dosing protocols, and outcome data.

Search compounds

Search the compound library by name or alias.

22 of 348 compounds match

Risk is a heuristic, not a medical safety rating. Low does not mean safe.

How these filters work

Risk uses the same estimate as compound profiles: legal status, suppression, ancillary requirements, and anabolic rating. Missing data can fall back to Low.

Routes match any documented option, including experimental or formulation-specific routes. Read each result’s qualifications; matching a route is not a recommendation. Missing or unrecognized routes appear only under All routes.

Goals match an editorial score of at least 6/10 for that dimension, including compounds that qualify for several goals. Missing scores do not match a selected goal. These scores do not measure clinical evidence.

Require PCT shows compounds marked as requiring post-cycle therapy. When off, all compounds are included; an unmarked record does not establish that PCT is unnecessary.

Other

22

Compounds that don't fit cleanly into the other buckets — research chemicals, niche pharmacological tools, and miscellaneous performance/health agents.

Follistatin-344
Follistatin-344 occupies a specific, interesting niche in the physique-enhancement toolkit: it's a peptide used to coax growth in a stubborn, lagging muscle tha
Recovery 5/102–4wk

Documented routes: SubQ, IM

Stenabolic
Stenabolic (SR9009) earned its place in the recomp and endurance conversation for one reason: in the landmark 2013 rodent work, activating REV-ERBα in skeletal
Endurance 6/106–12wk

Documented routes: Oral, SubQ (experimental)

DSIP
DSIP sits in a different corner of the peptide world than the healing and GH-axis compounds most people start with. It's not a sedative, not a hormone, not a se
Recovery 6/102–8wk

Documented routes: SubQ, IM, IV, Intranasal

Doxazosin
Doxazosin is a long-acting selective α₁-blocker that has quietly become a staple ancillary in the physique community — not as a primary antihypertensive, but as
Recovery 4/104–20wk

Documented routes: Oral

DMAA
DMAA earned its reputation in the pre-workout era for a reason: 25–50 mg pre-training delivers a clean, focused noradrenergic push that caffeine alone can't rep
Cognition 6/104–8wk

Documented routes: Oral

SR9011
Why SR9011 Gets Attention SR9011 is a synthetic REV-ERBα/β agonist from the Scripps series that kicked off the "exercise-mimetic" conversation in the mid-2010
Endurance 5/106–12wk

Documented routes: Oral

ACE-031
ACE-031 is one of the more interesting curiosities in the myostatin-inhibitor space — a soluble ActRIIB-Fc fusion protein that acts as a decoy receptor, soaking
Muscle 5/104–8wk

Documented routes: SubQ, IM

Trevogrumab
Trevogrumab: The First Clean Anti-Myostatin Antibody With Real Body-Recomp Data Trevogrumab (REGN1033) is Regeneron's fully human IgG4 monoclonal antibody aga
Muscle 3/1026–52wk

Documented routes: IV infusion, SubQ (explored in PK studies)

Thymogen
Thymogen: The Quiet Immune Reset Thymogen is the α-glutamyl-tryptophan dipeptide — a two-amino-acid fragment of thymopoietin-II that punches well above its mo
Recovery 5/101–2wk

Documented routes: SubQ, IM, Intranasal

Vasoactive Intestinal Peptide
Why VIP Is on the Radar Vasoactive Intestinal Peptide sits in an unusual corner of the peptide world. It's not a mass-builder, not a fat-loss agent, and not a
Recovery 6/104–24wk

Documented routes: Intranasal, Inhaled (aerosol), IV, SubQ

Nitroglycerin
Nitroglycerin is one of the oldest vasodilators in the pharmacopeia, but the bodybuilding and looksmaxxing community cares about it for two very specific reason
Recovery 7/101–24wk

Documented routes: Topical ointment, Transdermal patch, Sublingual, Rectal, IV (hospital only)

GW-0742
What GW-0742 Actually Does GW-0742 is the more potent sibling of cardarine (GW-501516) — a synthetic PPARδ agonist with ~1,000-fold selectivity over PPARα and
Endurance 8/106–12wk

Documented routes: Oral